已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an in Vitro model of a High-Risk Acute Lymphoblastic Leukemia

鲁索利替尼 医学 癌症研究 免疫学 内科学 肿瘤科 药理学 骨髓纤维化 骨髓
作者
Charlotte E J Downes,Barbara J. McClure,Jacqueline Rehn,James Breen,John B. Bruning,David T. Yeung,Deborah L. White
出处
期刊:Blood [Elsevier BV]
卷期号:136 (Supplement 1): 5-6 被引量:2
标识
DOI:10.1182/blood-2020-133491
摘要

Introduction Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of ALL associated with high relapse rates and poor survival. Rearrangements of Janus kinase 2 (JAK2r) are present in approximately 5% and 14% of pediatric and young adult Ph-like ALL cases respectively. The resultant JAK2 gene fusions drive leukemogenesis through constitutive activation of the JAK/STAT signaling pathway and are associated with very poor outcomes in patients with Ph-like ALL. All JAK inhibitors in clinical development are type I inhibitors, which bind in the ATP-binding site of JAK2. A phase II clinical trial is currently assessing the only FDA-approved JAK1/2 inhibitor, ruxolitinib in high-risk B-cell ALL cases harboring JAK2 alterations. The development of treatment resistance to targeted inhibitors in other diseases is well documented and often results in disease relapse. Elucidating mechanisms of ruxolitinib resistance in JAK2r ALL will inform approaches to monitor the emergence of resistance in ongoing clinical trials and enable the development of therapeutic strategies to overcome or avert resistance. Methods JAK2r B-ALL was modelled in the pro-B cell line, Ba/F3, by expressing the high-risk B-ALL fusion, ATF7IP-JAK2. Ruxolitinib resistance in three independent ATF7IP-JAK2 Ba/F3 cell lines was achieved following dose escalation to a clinically relevant dose of 1 μM ruxolitinib. Sanger sequencing of the RT-PCR amplified JAK2 fusion revealed each resistant line had acquired a different mutation within the JAK2 kinase domain. Therapeutic sensitives were assessed by staining with Fixable Aqua Dead Cell Stain (Invitrogen) and Annexin V, and analysis by flow cytometry. Alterations in signaling pathways were determined using phosphoflow cytometry and western blot analysis. Computational modelling of acquired JAK2 mutations and subsequent influence on ruxolitinib binding was performed using ICM-Pro (Molsoft L.C.C.). Results In addition to the identification of two known ruxolitinib resistant mutations, JAK2 p.Y931C and p.L983F, a novel p.G993A mutation was identified. All mutations localized to the ATP/ruxolitinib binding site and conferred resistance to multiple type-I JAK inhibitors, including ruxolitinib, BMS-911543, and AZD-1480 (Table 1). JAK2 p.G993A ATF7IP-JAK2 Ba/F3 cells were also resistant to the type-II JAK inhibitor, CHZ-868, which binds in an allosteric site of JAK2 in addition to the ATP-binding site. Ruxolitinib resistance correlated with sustained downstream STAT5 activation in the presence of 1 μM ruxolitinib compared with non-mutant ATF7IP-JAK2 Ba/F3 cells. Intracellular phosphoflow cytometry of ruxolitinib-resistant ATF7IP-JAK2 Ba/F3 cells confirmed constitutive activation of JAK/STAT signaling in the presence of 50 nM ruxolitinib, in contrast to non-mutant ATF7IP-JAK2 Ba/F3 cells. Computational modelling suggested that JAK2 p.L983F (Fig. 1D) sterically hinders ruxolitinib binding, while JAK2 p.Y931C may reduce ruxolitinib binding affinity by disruption of a critical hydrogen-bond (Fig. 1B). The novel JAK2 p.G993A mutation is predicted to alter DFG-loop dynamics by stabilizing the JAK2 activation loop (Fig1C). Conclusions This study demonstrates that the JAK2 ATP-binding site is susceptible to JAK inhibitor resistant mutations following ruxolitinib exposure in the setting of JAK2r ALL, highlighting the importance of monitoring the emergence of mutations within this region. In addition to previously described mutations we identified a novel JAK2 p.G993A mutation that conferred resistance to both type-I and type-II JAK inhibitors. The JAK2 p.G993A mutation was postulated to modulate the stability of a conserved domain. Understanding mechanisms of ruxolitinib resistance, as modelled here, has the potential to inform future drug design and the development therapeutic strategies for this high-risk cohort. Disclosures White: Amgen: Honoraria; Bristol-Myers Squibb: Honoraria, Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被依依加油发文章采纳,获得10
刚刚
刚刚
山有树完成签到 ,获得积分10
3秒前
云梦泽完成签到 ,获得积分10
5秒前
5秒前
allover完成签到,获得积分10
12秒前
judy发布了新的文献求助10
12秒前
13秒前
多鱼完成签到,获得积分10
14秒前
20秒前
jamesmo发布了新的文献求助30
21秒前
yu完成签到 ,获得积分10
22秒前
jcz完成签到,获得积分10
23秒前
24秒前
科研通AI6.4的应助被微解感染采纳,获得10
24秒前
JIE完成签到,获得积分10
28秒前
孤独的万恶完成签到 ,获得积分10
33秒前
Xi发布了新的文献求助60
34秒前
ni完成签到 ,获得积分20
34秒前
友好灵阳完成签到 ,获得积分10
35秒前
无花果的应助被2567285426采纳,获得10
36秒前
jamesmo完成签到,获得积分10
36秒前
yueqi完成签到,获得积分10
37秒前
愉快的真的应助被屈屈采纳,获得100
37秒前
铁打的雨点完成签到,获得积分10
38秒前
39秒前
小马完成签到,获得积分10
40秒前
zyyyyyy发布了新的文献求助10
40秒前
syvshc的应助被微解感染采纳,获得10
40秒前
合适雨完成签到,获得积分10
41秒前
dudu完成签到 ,获得积分10
42秒前
wanci的应助被lSj采纳,获得10
42秒前
sshuo发布了新的文献求助10
43秒前
言默完成签到,获得积分20
44秒前
趣多多发布了新的文献求助10
44秒前
46秒前
46秒前
何在完成签到,获得积分10
47秒前
53秒前
BugerKing完成签到 ,获得积分10
54秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194853
求助须知:如何正确求助?哪些是违规求助? 9580631
关于积分的说明 21872074
捐赠科研通 7794509
什么是DOI,文献DOI怎么找? 3437779
关于科研通互助平台的介绍 2561109
邀请新用户注册赠送积分活动 2484488